Quantcast

Study Demonstrates Benefits of MicroPulse(TM) Photocoagulation Over Current Standard Laser Treatment of Diabetic Macular Edema

May 4, 2011

MOUNTAIN VIEW, Calif., May 4, 2011 /PRNewswire/ — IRIDEX Corporation (Nasdaq: IRIX) today announced that leading clinicians have performed and published the results of a new study* that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers, over the standard-of-care protocol for the treatment of eyes with diabetic macular edema (DME). The results indicated that treating using MicroPulse mode was as effective as the standard-of-care protocol in treating DME but with the added advantages of causing no localized laser scars and significantly improving visual acuity. DME is damage to the retina caused by diabetes, and is the leading cause of blindness in persons under 50 years of age in the developed world. DME affects an estimated 2 million in the U.S. alone.

“This study is another important step in demonstrating the value of MicroPulse technology for the treatment of DME,” said Theodore A. Boutacoff, President and CEO. “The prevailing wisdom has been that it was necessary to cause localized damage to the retinal tissue in order to achieve the desired therapeutic effect. In recent years, this view has been challenged by evidence that using a MicroPulse dosing mode can achieve a treatment outcome for DME, which is comparable to the current standard-of-care laser therapy without producing damage and resulting scarring. This study confirms those findings and, in fact, shows an improvement in visual acuity following treatment. We believe this is another step towards what could be a paradigm shift in ophthalmic laser eye treatment.”

The recent online publication of the peer-reviewed clinical study compared results obtained in the treatment of DME with a subthreshold diode laser MicroPulse photocoagulation treatment protocol to those obtained using modified Early Treatment of Diabetic Retinopathy Study (mETDRS) laser protocol, the currently recognized standard-of-care. At one year, the prospective, randomized, controlled, double-masked clinical study demonstrated that a subthreshold diode laser MicroPulse protocol was as effective as the mETDRS protocol in the treatment of DME. Moreover, visual acuity significantly improved in eyes in the subthreshold diode laser MicroPulse treated group compared to the mETDRS group. All eyes in the mETDRS group developed localized laser scars, which were rarely found in eyes treated in the subthreshold diode laser MicroPulse group.

The authors conclude:

  • At one year, the clinical performance of high-density subthreshold diode laser MicroPulse photocoagulation was superior to that of the modified ETDRS photocoagulation technique based on the anatomic and functional measures of improvement used in this investigation.
  • The fact that a significant outcome can be obtained with less damaging laser treatments is an encouraging and a highly desirable clinical achievement.
  • Overall, the superior therapeutic response of high-density subthreshold diode laser MicroPulse may constitute the “proof of principle” that more destructive laser lesions would be unnecessary in macular laser photocoagulation for DME.
  • The benefits of this selective retina-sparing treatment, raises the possibility of improving the gold standard.

“This is the first randomized study to demonstrate a significant improvement in best corrected visual acuity using subthreshold diode laser MicroPulse treatment compared to the standard mETDRS laser photocoagulation treatment of DME and it is the second randomized study which has demonstrated a significant improvement in visual function,” continued Boutacoff. “This study is important as it also makes a significant milestone contribution towards optimizing the laser treatment technique by validating the superiority of the high-density subthreshold diode laser MicroPulse protocol.”

The study, conducted at the Hospital de Olhos de Araraquara and at the Federal University of Sao Paulo, Brazil, prospectively randomized 123 patients with previously untreated DME and best corrected visual acuity worse than 20/40 and better than 20/400 into one of three treatment arms: an mETDRS treatment arm using a standard green laser photocoagulator, a standard-density subthreshold diode laser MicroPulse treatment arm and a high-density subthreshold diode laser MicroPulse treatment arm. At one year, the mETDRS and the high-density subthreshold diode laser MicroPulse treatment groups demonstrated statistically significant improvements in central retinal thickness measurement and visual acuity from baseline. The improvement in visual acuity was significantly higher in the high-density subthreshold diode laser MicroPulse treatment group (+12 letters) compared to the conventional mETDRS treatment group (+4 letters). The percentage of eyes that improved 3 or more lines (15 letters) was 48% in the high-density subthreshold diode laser MicroPulse treated group compared to 23% in the mETDRS treated group.

About MicroPulse Technology

MicroPulse technology a tissue sparing laser delivery modality that works by electronically “chopping” the laser emission into trains of microsecond pulses. This enhances the physician’s ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment options of equal or greater effectiveness, and with less collateral effects than conventional laser treatments.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company’s website at http://www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to clinical practices with respect to ophthalmic laser eye treatments and shifts in the standard-of-care for treating diabetic macular edema. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of certain other risks relating to our business contained in our Annual Report on Form 10-K for the fiscal year ended January 1, 2011, which was filed with the Securities and Exchange Commission on March 25, 2011. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

* Lavinsky D, Cardillo J, Mello L, Dare A, Farah M, Belfort R. Randomized clinical trial evaluating mETDRS versus normal or high-density MicroPulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci, (in Press) Feb. 23, 2011 manuscript iovs.10-6628

SOURCE IRIDEX Corporation


Source: newswire



comments powered by Disqus